Update on the therapy of highly aggressive non-Hodgkin's lymphoma

Eric Jacobsen; Ann LaCasce

doi:10.1517/14712598.6.7.699

Update on the therapy of highly aggressive non-Hodgkin's lymphoma

Expert Opin Biol Ther. 2006 Jul;6(7):699-708. doi: 10.1517/14712598.6.7.699.

Authors

Eric Jacobsen¹, Ann LaCasce

Affiliation

¹ Dana-Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA. [email protected]

PMID: 16805709
DOI: 10.1517/14712598.6.7.699

Abstract

This review focuses on the current understanding of the biology of highly aggressive non-Hodgkin's lymphomas, such as Burkitt's lymphoma, lymphoblastic lymphoma and adult T cell lymphoma/leukaemia. Specifically, this review will examine how our increased understanding of the pathophysiology of these diseases can be used to develop new therapies.

Publication types

Review

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Burkitt Lymphoma* / drug therapy
Burkitt Lymphoma* / physiopathology
Child
Female
Humans
Lymphoma, Non-Hodgkin* / drug therapy
Lymphoma, Non-Hodgkin* / mortality
Lymphoma, Non-Hodgkin* / physiopathology
Lymphoma, T-Cell* / drug therapy
Lymphoma, T-Cell* / physiopathology
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / physiopathology